Literature DB >> 12810673

Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.

Oliver Stoeltzing1, Syed A Ahmad, Wenbiao Liu, Marya F McCarty, Jane S Wey, Alexander A Parikh, Fan Fan, Niels Reinmuth, Michiya Kawaguchi, Corazon D Bucana, Lee M Ellis.   

Abstract

Angiopoietin (Ang)-1 and -2 are critical regulators of embryonic and postnatal neovascularization. Ang-1 activates the endothelial cell-specific tyrosine kinase receptor Tie-2, which in turn leads to enhanced endothelial cell survival and stabilization. The effects of Ang-1 on tumor angiogenesis remain controversial; although we have previously demonstrated that Ang-1 overexpression in colon cancer cells leads to a decrease in s.c. tumor growth, others have shown that Ang-1 may be proangiogenic. Few studies have addressed the role of the Angs in tumors growing in the organ of metastatic growth. We hypothesized that overexpression of Ang-1 may inhibit the growth of colon cancers growing in the liver by inhibition of angiogenesis. We also wanted to investigate the mechanisms by which Ang-1 affects angiogenesis in vivo. Human colon cancer cells (HT29) were stably transfected with an Ang-1 construct or an empty vector (pcDNA) and injected directly into the livers of nude mice. After 37 days, livers were harvested and weighed, and tumor sizes were measured. In an additional experiment, to validate the paracrine effect of Ang-1, various mixtures of control cells and Ang-1-transfected cells were injected into livers, and tumor growth was assessed. Direct effects of recombinant Ang-1 on angiogenesis were studied with an in vivo Gelfoam angiogenesis assay. The impact of Ang-1 on vascular permeability was investigated using an intradermal Miles assay with conditioned media from transfected cells. Liver weights (P < 0.05), tumor volumes (P < 0.05), vessel counts (P < 0.01), and tumor cell proliferation (P < 0.01) in the Ang-1 group were significantly lower than those in the control (pcDNA) group. Tumor vessels in the Ang-1 group developed a significantly higher degree of pericyte coverage (P < 0.02) than vessels in pcDNA tumors. In the cell mixture experiment, even as few as a 1:10 mixture of Ang-1-transfected cells/control cells resulted in a significant reduction of hepatic tumor volumes (P < 0.04). In the angiogenesis assay, vessel counts in Gelfoam implants were significantly decreased by the addition of Ang-1 (P < 0.01). Finally, conditioned medium from Ang-1-transfected cells decreased vascular permeability more than that from control cells (P < 0.05). Our results suggest that Ang-1 is an important regulator of angiogenesis and vascular permeability and that this effect may be secondary to increasing periendothelial support and vessel stabilization. Thus, Ang-1 could potentially serve as an antineoplastic or anti-permeability agent for patients with metastatic colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810673

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Activating transcription factor 3 promotes colon cancer metastasis.

Authors:  Zhi-Yong Wu; Zheng-Mao Wei; Sheng-Jie Sun; Jing Yuan; Shun-Chang Jiao
Journal:  Tumour Biol       Date:  2014-05-24

2.  Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

Authors:  Sonja Loges; Thomas Schmidt; Peter Carmeliet
Journal:  Genes Cancer       Date:  2010-01

3.  Antisense angiopoietin-1 inhibits tumorigenesis and angiogenesis of gastric cancer.

Authors:  Jun Wang; Kai-Chun Wu; De-Xin Zhang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions.

Authors:  Jeong-Ju Yoo; Dong Hyeon Lee; Yuri Cho; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Chung Yong Kim; Jung-Hwan Yoon
Journal:  J Bioenerg Biomembr       Date:  2016-09-17       Impact factor: 2.945

5.  Unique angiogenic and vasculogenic properties of renal cell carcinoma in a xenograft model of bone metastasis are associated with high levels of vegf-a and decreased ang-1 expression.

Authors:  Chao Xie; Edward M Schwarz; Erik R Sampson; Robinder S Dhillon; Dan Li; Regis J O'Keefe; Wakenda Tyler
Journal:  J Orthop Res       Date:  2011-08-01       Impact factor: 3.494

Review 6.  Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.

Authors:  Hellmut G Augustin; Gou Young Koh; Gavin Thurston; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

7.  Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.

Authors:  Sven Arke Lang; Isabel Brecht; Christian Moser; Aiman Obed; David Batt; Hans Juergen Schlitt; Edward Kenneth Geissler; Oliver Stoeltzing
Journal:  Langenbecks Arch Surg       Date:  2008-02-23       Impact factor: 3.445

8.  Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1.

Authors:  Elisa Boscolo; John B Mulliken; Joyce Bischoff
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-01-03       Impact factor: 8.311

9.  Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade.

Authors:  Jianzhong Huang; Jae-O Bae; Judy P Tsai; Angela Kadenhe-Chiweshe; Joey Papa; Alice Lee; Shan Zeng; Z Noah Kornfeld; Paivi Ullner; Nibal Zaghloul; Ella Ioffe; Sarah Nandor; Elena Burova; Jocelyn Holash; Gavin Thurston; John Rudge; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Int J Oncol       Date:  2009-01       Impact factor: 5.650

10.  Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1).

Authors:  Christopher Daly; Vivian Wong; Elena Burova; Yi Wei; Stephanie Zabski; Jennifer Griffiths; Ka-Man Lai; Hsin Chieh Lin; Ella Ioffe; George D Yancopoulos; John S Rudge
Journal:  Genes Dev       Date:  2004-05-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.